Tag: Combination Therapy for Urothelial Carcinoma

Home / Combination Therapy for Urothelial Carcinoma

Categories

Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial carcinoma

Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant...
combination-therapy-for-urothelial-carcinoma

Scan the code